Literature DB >> 16951231

Aurora kinase A messenger RNA overexpression is correlated with tumor progression and shortened survival in head and neck squamous cell carcinoma.

Rudolf Reiter1, Peter Gais, Uta Jütting, Miriam K Steuer-Vogt, Anja Pickhard, Karin Bink, Sandra Rauser, Silke Lassmann, Heinz Höfler, Martin Werner, Axel Walch.   

Abstract

PURPOSE: Aurora kinase A (AURKA/STK15/BTAK) encodes a serine/threonine kinase associated with chromosomal distribution and its up-regulation induces chromosomal instability, thereby leading to aneuploidy and cell transformation in several types of cancer. In this study, we investigated the role of AURKA in head and neck squamous cell carcinoma (HNSCC). EXPERIMENTAL
DESIGN: The mRNA expression levels of AURKA were compared in tumor tissues of 66 HNSCC patients with those in corresponding normal squamous epithelium by real-time quantitative reverse transcriptase-PCR. In addition, the association between AURKA mRNA and protein expression, centrosome abnormalities, and aneuploidy was studied in a subset of cases (n=34). All molecular variables were correlated to histomorphologic findings and clinical follow-up data of the patients.
RESULTS: AURKA mRNA up-regulation was significantly associated with tumor stage and the occurrence of regional lymph node, as well as distant metastasis (P<0.0001 for all). Similarly, a correlation was found for protein expression and the occurrence of regional lymph node (P=0.0183) and distant metastasis (P=0.03). The mRNA was positively associated with protein expression (P=0.003) and centrosome abnormalities (P=0.03). Cox regression analysis revealed that AURKA mRNA up-regulation correlated with disease-free survival of the patients (P=0.03) as well as shorter overall survival (P<0.001).
CONCLUSIONS: We conclude that the up-regulation of AURKA mRNA may play a critical role in the tumor progression of HNSCC and provides useful information as a prognostic factor for HNSCC patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16951231     DOI: 10.1158/1078-0432.CCR-05-1650

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  76 in total

1.  Inhibition of Aurora kinases enhances chemosensitivity to temozolomide and causes radiosensitization in glioblastoma cells.

Authors:  Kleiton Silva Borges; Angel Maurício Castro-Gamero; Daniel Antunes Moreno; Vanessa da Silva Silveira; Maria Sol Brassesco; Rosane Gomes de Paula Queiroz; Harley Francisco de Oliveira; Carlos Gilberto Carlotti; Carlos Alberto Scrideli; Luiz Gonzaga Tone
Journal:  J Cancer Res Clin Oncol       Date:  2011-12-09       Impact factor: 4.553

Review 2.  Aurora kinases in head and neck cancer.

Authors:  Ranee Mehra; Ilya G Serebriiskii; Barbara Burtness; Igor Astsaturov; Erica A Golemis
Journal:  Lancet Oncol       Date:  2013-09       Impact factor: 41.316

Review 3.  Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinic.

Authors:  Muneera Al-Hussaini; John F DiPersio
Journal:  Expert Rev Hematol       Date:  2014-08       Impact factor: 2.929

4.  Structural studies of B-type Aurora kinase inhibitors using computational methods.

Authors:  Mm Neaz; M Muddassar; Fa Pasha; Seung Joo Cho
Journal:  Acta Pharmacol Sin       Date:  2010-02       Impact factor: 6.150

5.  The molecular mechanism studies of chirality effect of PHA-739358 on Aurora kinase A by molecular dynamics simulation and free energy calculations.

Authors:  Yuanhua Cheng; Wei Cui; Quan Chen; Chen-Ho Tung; Mingjuan Ji; Fushi Zhang
Journal:  J Comput Aided Mol Des       Date:  2011-01-11       Impact factor: 3.686

6.  AURKA Phe31Ile polymorphism interacted with use of alcohol, betel quid, and cigarettes at multiplicative risk of oral cancer occurrence.

Authors:  Chi-Pin Lee; Shang-Lun Chiang; Chien-Hung Lee; Yi-Shan Tsai; Zhi-Hong Wang; Chun-Hung Hua; Yuan-Chien Chen; Eing-Mei Tsai; Ying-Chin Ko
Journal:  Clin Oral Investig       Date:  2015-02-21       Impact factor: 3.573

7.  Probing the structural requirements of A-type Aurora kinase inhibitors using 3D-QSAR and molecular docking analysis.

Authors:  Hui-Xiao Zhang; Yan Li; Xia Wang; Yong-Hua Wang
Journal:  J Mol Model       Date:  2011-04-28       Impact factor: 1.810

8.  Aurora kinase A (AURKA) and never in mitosis gene A-related kinase 6 (NEK6) genes are upregulated in erosive esophagitis and esophageal adenocarcinoma.

Authors:  Elmas Kasap; Seda Örenay Boyacioglu; Mehmet Korkmaz; Elif Saritas Yuksel; Belkis Unsal; Erkan Kahraman; Omer Ozütemiz; Hakan Yuceyar
Journal:  Exp Ther Med       Date:  2012-04-25       Impact factor: 2.447

Review 9.  Centrosome-associated regulators of the G(2)/M checkpoint as targets for cancer therapy.

Authors:  Yingmei Wang; Ping Ji; Jinsong Liu; Russell R Broaddus; Fengxia Xue; Wei Zhang
Journal:  Mol Cancer       Date:  2009-02-13       Impact factor: 27.401

10.  Effect of the drug transporters ABCG2, Abcg2, ABCB1 and ABCC2 on the disposition, brain accumulation and myelotoxicity of the aurora kinase B inhibitor barasertib and its more active form barasertib-hydroxy-QPA.

Authors:  Serena Marchetti; Dick Pluim; Monique van Eijndhoven; Olaf van Tellingen; Roberto Mazzanti; Jos H Beijnen; Jan H M Schellens
Journal:  Invest New Drugs       Date:  2013-01-13       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.